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Abstract 17 
 18 
Background 19 
MYCN amplification (MNA) is the strongest indicator of poor prognosis in neuroblastoma (NB). This 20 
meta-analysis aims to determine the diagnostic accuracy of MNA analysis in circulating-free DNA 21 
(cfDNA) from advanced-stage NB patients.  22 
 23 
Methods 24 
A systematic review of electronic databases was conducted to identify studies exploring the detection 25 
of MNA in plasma/serum cfDNA from NB patients at diagnosis using PCR methodology. Pooled 26 
estimates for sensitivity, specificity and diagnostic odds ratio (DOR) were calculated by conducting a 27 
bivariate/HSROC random-effects meta-analysis.  28 
 29 
Results 30 
Seven studies, with a total of 529 advanced-stage patients, were eligible. The pooled sensitivity of 31 
cfDNA-based MNA analysis was 0.908 (95% CI, 0.818 – 0.956), the pooled specificity was 0.976 32 
(0.940 – 0.991) and the DOR was 410.0 (-103.6 – 923.7). Sub-grouped by INSS stage, the sensitivity 33 
for stage 3 and 4 patients was 0.832 (0.677 – 0.921) and 0.930 (0.834 – 0.972), respectively. The 34 
specificity was 0.999 (0.109 – 1.000) and 0.974 (0.937 – 0.990), respectively, and the DOR was 35 
7855.2 (-66267.0 – 81977.4) and 508.7 (-85.8 – 1103.2), respectively.  36 
 37 
Conclusions 38 
MNA analysis in cfDNA using PCR methodology represents a non-invasive approach to rapidly and 39 
accurately determine MNA status in patients with advanced-stage NB. Standardised methodology 40 
must be developed before this diagnostic test can enter the clinic.  41 
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Background 44 
MYCN amplification (MNA) is detected in around 20% of neuroblastoma patients (NB) (1). MNA 45 
is associated with advanced tumour stage and rapid disease progression, and it is the strongest 46 
indicator of poor prognosis for NB (2). Methods currently used to determine MNA status include 47 
interphase fluorescence in situ hybridisation (FISH), polymerase chain reaction (PCR), multiplex 48 
ligation-dependent probe amplification (MLPA) and array comparative genomic hybridisation (aCGH) 49 
on tumour material obtained via biopsy (3). While FISH has been the gold standard technique for 50 
analysis of gene dosage in cancer specimens over the past few decades, it involves subjective 51 
evaluation of images by experienced diagnosticians and requires a fluorescent microscope to assess 52 
large cell populations (4).  53 
The biopsy process required for tissue analysis is invasive, and tumours are not always 54 
accessible for genetic analysis. Moreover, analysis of biopsy material can be confounded in tumours 55 
with an abundance of non-malignant cells (5) and with heterogeneous patterns of MNA (6,7); in recent 56 
studies, intratumoural heterogeneity with respect to MNA has been estimated to occur at a frequency  57 
of 9.7 – 10.3% (8,9). An alternative approach to MNA analysis involves PCR-based analysis of MYCN 58 
copy number in circulating-free DNA (cfDNA) isolated from plasma or serum (10). This ‘liquid biopsy’ 59 
is minimally invasive and may overcome genetic heterogeneity as the method surveys aggregate 60 
tumour DNA shed into blood (11). In addition, the rapidity of blood processing and PCR analysis 61 
enables fast determination of MNA status and assignment of the appropriate therapy for critically ill 62 
patients, with a potential sample-to-result turnaround time of less than a day (12). 63 
The detection of MNA in cfDNA of NB patients was first demonstrated by Combaret and 64 
colleagues in 2002 using a simple qPCR assay targeting MYCN and a reference gene (RPPH1) (13). 65 
The authors reported high concordance of the MNA status between tumour and serum samples 66 
across all disease stages. Subsequent studies have used (q)PCR assays targeting MYCN and NAGK 67 
(also on chromosome 2p) and have consistently reported high sensitivity and specificity for MNA 68 
analysis in cfDNA of patients with advanced disease (14–19). For example, Yagyu et al. recently 69 
reported a sensitivity and specificity of 0.87 (95% CI, 0.72 – 0.96) and 0.97 (95% CI, 0.84 – 1.0) 70 
among 71 patients with stage 4 NB (17). While no clinical trials of NB have formally incorporated 71 
cfDNA-based MNA analysis, the aforementioned studies have recruited several hundred patients 72 
across multiple disease stages and used similar PCR methodology to measure MYCN copy number 73 
(14–19). Here, we perform a meta-analysis to determine the diagnostic accuracy of MNA analysis in 74 
cfDNA from patients with advanced-stage (INSS stage 3 and 4) NB.  75 
 76 
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Methods 87 
This meta-analysis was designed and executed in accordance with PRISMA-DTA reporting guidelines 88 
(20). 89 
 90 
Literature search  91 
A comprehensive literature search was undertaken to identify all published studies reporting the 92 
sensitivity and specificity of cfDNA-based MYCN analysis using PCR methodology. The following 93 
electronic databases were searched from inception to August 2019: the Cochrane Central Register of 94 
Controlled Trials (CENTRAL), EMBASE, PubMed/MEDLINE and Web of Science Conference 95 
Proceedings Citation Index – Science (CPCI-S). The search strategy comprised the terms 96 
“neuroblastoma”, “MYCN”, “circulating-free DNA” and terms synonymous with “circulating-free DNA”, 97 
including “ccfDNA”,  “cfDNA”, “ctDNA”, “cell-free DNA”, “cell free DNA”, “circulating DNA”, “circulating 98 
free DNA”, “circulating tumour DNA”, “free DNA”, “free tumour DNA”, “plasma” and “serum”. Keywords 99 
were combined using Boolean operators, translated into database-specific syntax, and searched for in 100 
the title and abstract only. The search was limited to the English language. Supplementary 101 
Information 1 details the search strings used for each database. Additional studies were identified 102 
through a manual search of bibliographies in included studies and relevant narrative reviews. Authors 103 
of the following publications were contacted by email for further information: Combaret et al. 2005, 104 
Combaret et al. 2009 and Yagyu et al. 2016.  105 
 106 
Selection criteria 107 
Studies investigating the detection of MNA in plasma or serum cfDNA of NB patients at diagnosis 108 
using PCR methodology proceeded to full-text review. The criteria for inclusion were as follows: 1) 109 
diagnosis of neuroblastoma confirmed by tumour histology; and 2) matched cfDNA and tumour biopsy 110 
material; and 3) use of PCR methodology to detect MNA. The criteria for exclusion were as follows: 1) 111 
insufficient data available to determine diagnostic accuracy using 2x2 tables (after author contact); 2) 112 
absence of disease stage data; and 3) duplicate publication. All included and excluded studies were 113 
verified for eligibility by two independent reviewers (R.M.T. and L.J.). 114 
 115 
Data extraction 116 
The following data were independently extracted into an electronic table and assessed by R.M.T. and 117 
L.J.: first author name, journal, year of publication, number of patients, baseline patient characteristics 118 
(age, gender and INSS tumour stage), blood specimen type (plasma or serum), cfDNA isolation 119 
method, MYCN PCR method, true positive (TP), false negative (FN), true negative (TN) and false 120 
positive (FP) rates.  121 
 122 
4 
Quality assessment 123 
The overall quality of the included studies was determined by two independent reviewers (R.M.T. and 124 
L.J.) using QUADAS-2 (21), a tool developed for the quality assessment of diagnostic accuracy 125 
studies. This tool comprises four domains: patient selection, index test, reference standard, and flow 126 
and timing, and each domain is assessed for risk of bias and applicability. 127 
 128 
Statistical analysis 129 
MNA status in biopsy tissue as determined by FISH or Southern blot was considered the reference 130 
standard. For each study and each INSS tumour stage, 2x2 contingency tables were populated with 131 
TP (MNA detected in both cfDNA and tumour tissue), FN (MNA detected in tumour tissue but not 132 
cfDNA), TN (MNA detected in neither cfDNA nor tumour tissue), and FP (MNA detected in cfDNA but 133 
not tumour tissue) data. Diagnostic odds ratio (DOR), sensitivity, specificity, positive likelihood ratio 134 
(PLR) and negative likelihood ratio (NLR) were calculated along with corresponding 95% confidence 135 
intervals (95% CI) for each study in Meta-DiSc v1.4 statistical software (22). Haldane-Anscombe 136 
correction (23,24) was used to avoid division by zero errors in contingency table data, where 137 
appropriate. 2x2 contingency data were imported into MetaDTA (25) 138 
(https://crsu.shinyapps.io/dta_ma_1_43/), a web-based application for fitting the binomial model of 139 
Chu & Cole (26). In MetaDTA, the model is fitted as a generalised linear mixed-effect model using the 140 
glmer function from the R package lme4 (27). Percentage study weights were calculated in MetaDTA 141 
based on a decomposition of Fisher’s information matrix, according to the recent methodology of 142 
Burke et al. (28) Deeks’ funnel plots were generated by plotting, for each study, the natural logarithm 143 
of the DOR against the inverse root of the effective sample size (ESS) (29). The ESS is calculated 144 
from the number of diseased (nd) and healthy (nh) subjects: (4*nd*nh)/(nd + nh). Deeks’ asymmetry test 145 
was conducted by linear regression analysis. 146 
 147 
 148 
 149 
Results 150 
 151 
Studies assessed 152 
A comprehensive search of electronic databases identified a total of 167 studies, with twelve 153 
studies reaching the initial criteria for inclusion. Studies were subsequently excluded due to the 154 
absence of data required to determine diagnostic accuracy (n = 4), absence of INSS stage data (n = 155 
4), and duplicate publication (n = 1), leaving a total of seven studies for meta-analysis (Figure 1). 156 
These studies, published between 2002 and 2016, recruited a total of 844 NB patients, most of whom 157 
were assessed for MNA status at diagnosis by FISH and/or Southern blot of biopsy tissue. All of the 158 
studies included employed qPCR (n = 6) and/or conventional PCR (n = 2) to analyse MNA in cfDNA 159 
isolated from plasma (n = 2) or serum (n = 6) using the QIAamp DNA Blood Kit (Qiagen). In 4/5 160 
studies that reported a cut-off for MYCN copy number in cfDNA, a stringent MYCN-to-reference ratio 161 
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of 5.0 could discriminate MNA+ and MNA- patients. The main characteristics of the studies included 162 
are summarised in Table 1. 163 
 164 
Diagnostic accuracy of cfDNA-based MNA analysis 165 
An initial analysis was conducted across all tumour stages (Supplementary Table 1). Since very 166 
few patients with localised (stage 1 and 2) or stage 4S disease were recruited to the seven studies, 167 
and MNA is uncommon, these patient sub-groups could not be reliably meta-analysed and were 168 
therefore excluded. Sensitivity, specificity and likelihood ratios for the remaining 529 patients with 169 
advanced-stage (stage 3 and 4) disease are reported for each study in Table 2.  170 
Further, we calculated estimated pooled data and performed sub-group analysis (Figure 2 and 3; 171 
Table 3 and 4). Specifically, using a bivariate random-effects model, the estimated pooled sensitivity 172 
of cfDNA was 0.908 (95% CI, 0.818 – 0.956) and the estimated pooled specificity was 0.976 (0.940 – 173 
0.991) (Figure 2A; Table 4). Estimates of the pooled positive and negative likelihood ratios (PLR, 174 
NLR) were 38.6 (1.8 – 75.5) and 0.094 (0.027 – 0.161), respectively. The pooled diagnostic odds ratio 175 
(DOR) was 410.0 (-103.6 – 923.7) (Table 4) and the pooled HSROC curve was calculated (Figures 176 
2B).   177 
To determine whether disease stage could significantly influence the accuracy of cfDNA-based 178 
MNA analysis, stage 3 and stage 4 patients were subjected to sub-group analyses. Per-study 179 
sensitivity, specificity and likelihood ratios for each stage are shown in Table 3. The estimated pooled 180 
sensitivity of cfDNA for patients with stage 3 and 4 disease was 0.832 (0.677 – 0.921) and 0.930 181 
(0.838 – 0.972), respectively, and the pooled specificity was 0.999 (0.109 – 1.000) and 0.974 (0.937 – 182 
0.990), respectively (Figures 3A and B; Table 4). The pooled PLR for stage 3 and 4 patients was 183 
1321.2 (-11172.2 – 13814.6) and 36.4 (3.6 – 69.3), respectively, and the pooled NLR was 0.168 184 
(0.048 – 0.288) and 0.072 (0.009 – 0.134), respectively (Table 4). The pooled DOR was 7855.2 (-185 
66267.0 – 81977.4) and 508.7 (-85.8 – 1103.2), respectively, and the pooled HSROC curves were 186 
generated (Figures 3C and D).   187 
 188 
Assessment of threshold effect and publication bias 189 
A Spearman’s correlation coefficient of -0.126 (p = 0.788) between sensitivity and 1-specificity 190 
indicated the absence of a threshold effect among the included studies. Furthermore, the ROC plane 191 
did not show a curvilinear pattern characteristic of a threshold effect (data not shown).  Further 192 
investigation of DOR revealed low heterogeneity due to non-threshold effect (data not shown). The 193 
potential for publication bias was visually assessed by Deeks’ funnel plot and statistically calculated 194 
by Deeks’ asymmetry test (29). No significant bias was found among the studies for stage 3 and 4 195 
combined (p = 0.881), stage 3 alone (p = 0.503) and stage 4 alone (p = 0.465) (Figure 4).  196 
  197 
Assessment of study quality  198 
The overall quality of the studies included in this meta-analysis was evaluated with QUADAS-2 199 
(21) (Figure 5). This tool was designed to evaluate individual studies on the basis of patient selection, 200 
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index test, reference standard, and flow and timing. Study quality was generally high with a low risk of 201 
bias and low concerns of applicability. However, none of the studies determined the MNA cut-off prior 202 
to analysis, and in three studies it was not specified whether the cfDNA analyses were conducted in a 203 
blind manner or with prior knowledge of tissue MNA status (reference standard).   204 
 205 
Discussion 206 
MNA status is a critical factor that informs the prognostic and therapeutic course of patients with 207 
NB (2). To overcome several limitations of MNA analysis in biopsy tissue at diagnosis, studies over 208 
the past two decades have investigated the utility of cfDNA in plasma or serum as a tumour surrogate 209 
(30). The aim of this meta-analysis was to determine the diagnostic accuracy of MNA analysis in 210 
cfDNA of patients with NB using FISH or Southern blot as the reference standard and a PCR method 211 
as the index test. The comprehensive search strategy identified twelve studies, of which seven were 212 
suitable for inclusion, assessing a total of 844 patients of all INSS stages. Reflecting the very low 213 
incidence of MNA in patients with stage 1, 2 and 4S disease (31–33), the seven included studies 214 
individually recruited few or no MNA-positive patients from these stage groups. Therefore, to avoid 215 
introducing significant bias to the analysis, this study did not include stage 1, 2 or 4S patients in the 216 
pooled or sub-group analyses, leaving 529 patients with advanced-stage (stage 3 and 4) disease. 217 
For patients with advanced-stage disease, pooled analysis showed that MNA status was 218 
determined with high sensitivity and almost perfect specificity (0.908 and 0.976, respectively). 219 
Consequently, the diagnostic accuracy was very high, with a DOR of 410.042. Given that the tumour-220 
derived fraction of cfDNA increases with tumour burden in many solid cancers including NB (34,35), it 221 
was considered necessary to perform a sub-group analysis on patients with stage 3 and stage 4 222 
disease. While the specificity for both patient sub-groups were 0.999 and 0.974 for stage 3 and 4, 223 
respectively, sensitivity was lower for patients with stage 3 disease relative to stage 4 (0.832 vs. 224 
0.930, respectively). This resulted in a higher global performance for metastatic disease, as expected, 225 
given the high tumour burden in these patients. It is noteworthy that while the rate of false positives in 226 
this meta-analysis was very low among stage 3 and 4 patients (2/137 and 6/392, respectively), these 227 
occurrences may be attributable to intratumoural heterogeneity with respect to MNA, leading to a 228 
negative result by FISH analysis of tissue and a positive result by PCR analysis of cfDNA. 229 
None of the included studies determined the cut-off MYCN/reference gene ratio to define MNA 230 
prior to analysis, and the implemented cut-off ratios were either wide-ranging or unreported. However, 231 
a threshold effect was ruled out by Spearman’s correlation coefficient and visual ROC plane analysis. 232 
Other aspects of study design were generally acceptable according to the QUADAS-2 framework 233 
(21). A distinct strength of this meta-analysis is the consistency in index test methodology between 234 
studies; all studies isolated cfDNA using the same commercial kit, employed a PCR technique and 235 
normalised MYCN to a single reference gene. A potential source of heterogeneity was in the use of 236 
plasma vs. serum as a source of cfDNA; whereas cfDNA in plasma is stable for several hours post-237 
venepuncture, a delay in processing of serum as well as contamination by white blood cells can result 238 
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in the release of genomic DNA into the sample, thus potentially masking detection of MYCN gene 239 
amplification by high levels of DNA from normal cells (36).  240 
The high diagnostic accuracy of cfDNA in advanced-stage patients, as demonstrated in this study, 241 
has promising implications for several clinical scenarios. In patients with surgically inaccessible 242 
tumours, or in patients who are critically unwell, a biopsy may not be possible (12), whereas blood 243 
collection is less invasive and repeatable if insufficient material is obtained at first attempt (37). 244 
Moreover, the rapidity of blood collection, automated cfDNA extraction and simple analysis enables 245 
fast determination of MNA status in patients who require immediate assignment to appropriate 246 
treatment. Analysis of cfDNA is also advantageous over tissue analysis in tumours exhibiting 247 
heterogeneous patterns of MNA (6,7); cfDNA may also have the potential to reveal MNA in patients 248 
with heterogeneity between their primary tumour and metastases (38) and provide a critical 249 
opportunity for additional therapeutic intervention. As with all technologies, there are limitations to this 250 
approach, as it requires that sufficient molecules are present in the plasma or serum at the time of 251 
collection, which may not be the case in patients with intratumoural heterogeneity and small, early-252 
stage tumours.  253 
While stage 4S disease was excluded from this meta-analysis, MNA is relativity uncommon in 254 
these patients and its prognostic significance is disputed (39–42). In contrast, MNA is firmly 255 
established as a poor prognostic indicator in patients with stage 1 and 2 disease, albeit occurring at a 256 
frequency of only 3–4% (31,32). Of the seven included studies, only four patients with MNA-positive 257 
stage 1 and 2 disease were reported. Combaret et al. (2009) reported a very low sensitivity of cfDNA 258 
analysis in stage 1 and 2 patients, with only one patient showing evidence of MNA in cfDNA among 259 
ten patients with MNA-positive tumours (43). This observation is not unexpected given evidence from 260 
other early-stage solid cancers to indicate that low tumour burden limits the detectability of tumour-261 
specific alterations in cfDNA (44,45), particularly copy number alterations due to the dilution effect of 262 
cfDNA derived from apoptosis of healthy blood cells. It is also noteworthy that genomic DNA 263 
contamination arising from lysed white blood cells with the delayed processing of serum is likely to 264 
disproportionately influence the sensitivity of MNA analysis in early-stage NB patients. Hence, future 265 
studies recruiting patients with stage 1 and 2 disease should consider plasma as the preferred 266 
specimen type.  267 
Molecular diagnostic laboratories are increasingly becoming equipped with next-generation 268 
sequencing platforms, and in the future, it may be possible to employ sequencing-based methods for 269 
analysis of MNA along with other prognostic or actionable genomic alterations in cfDNA. To this end, 270 
it has recently been shown that MNA among other alterations can be detected in the cfDNA of NB 271 
patients using shallow whole-genome/exome sequencing (46,47) and microarray methods (48). 272 
However, these studies must be replicated with larger patient cohorts in a diagnostic setting before a 273 
meta-analysis can be undertaken. 274 
 275 
Conclusion 276 
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       In conclusion, this is the first systematic review and meta-analysis of the diagnostic performance 277 
of cfDNA for the determination of MNA status in patients with advanced-stage NB. The studies 278 
assessed used simple and widely available tests (PCR or qPCR), highlighting the potential of 279 
implementing a straightforward and inexpensive blood-based diagnostic test for use in patients who 280 
are too unwell for surgery or where biopsy is not possible. Standardised methodology for cfDNA 281 
analysis should be developed and incorporated into future large-scale prospective trials for clinical 282 
validation and to determine the effects of therapy on plasma/serum MNA status. 283 
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Figures 450 
 451 
Figure 1. Flow chart for study selection based on PRISMA-DTA guidelines. 452 
 453 
Figure 2. (A) Forest plots of sensitivity and specificity of cfDNA-based MNA analysis at diagnosis in 454 
NB patients with advanced-stage disease. (B) Hierarchical Summary receiver operator characteristic 455 
(HSROC) curve analysis for patients with advanced-stage (stage 3 and 4) disease. 456 
 457 
Figure 3. (A,B) Forest plots of sensitivity and specificity of cfDNA-based MNA analysis at diagnosis in 458 
NB patients with (A) stage 3 and (B) stage 4 disease.  (C,D) Hierarchical Summary receiver operator 459 
characteristic (HSROC) curve analysis for patients with (C) stage 3 and (D) stage 4 disease. 460 
 461 
Figure 4. Deeks’ funnel plots of DOR for cfDNA-based MNA analysis in (A) stage 3 and 4, (B) stage 462 
3 and (C) stage 4 NB patients. Each point represents the natural logarithm of the DOR of a study 463 
plotted against the square root of its effective sample size (ESS).  464 
 465 
Figure 5. Quality assessment of studies by QUADAS-2. 466 
 467 
 468 
Tables 469 
 470 
Table 1. Main characteristics of included studies. FISH, fluorescence in situ hybridisation; NR, not 471 
reported; SB, Southern blot; QDB kit, QIAamp DNA Blood kit. 472 
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Table 2. Sensitivity, specificity and likelihood ratios for each study in patients with advanced-stage 474 
(stage 3 and 4) NB. 475 
 476 
Table 3. Sensitivity, specificity and likelihood ratios for each study in patients sub-grouped by stage. 477 
 478 
Table 4. Summary of the diagnostic accuracy of MNA assessment in cfDNA of patients with stage 3 479 
and/or 4 NB. 480 





 Study Location 
Patient n by INSS stage  
(MNA+/MNA-) Reference 
standard Blood specimen
cfDNA 
isolation kit 
MNA cut-
off Assay 
Reference 
gene 
1+2 3 4 4S 
Combaret et al. 200213 France 1/24 5/8 25/33 1/5 SB plasma/serum QDB kit NR qPCR RPPH1 
Gotoh et al. 200514 Japan 2/40 2/7 13/18 0/5 SB serum QDB kit (5 to) 10 qPCR NAGK 
Combaret et al. 200512 France, Spain 0/25 4/19 11/19 1/6 SB serum QDB kit NR PCR IL1B 
Combaret et al. 200915 Europe, USA 10/24 16/27 41/83 6/60 SB/FISH serum QDB kit 5 qPCR NAGK 
Kojima et al. 201316 Japan 0/20 2/7 14/6 0/1 SB/FISH plasma QDB kit 2-5 qPCR NAGK 
Yagyu et al. 201617 Japan, USA 6/38 12/14 38/33 1/6 SB/FISH serum QDB kit 5 qPCR NAGK 
Ma et al. 201618 South Korea 0/31 1/13 9/49 0/2 FISH serum QDB kit 1.6 PCR NAGK 
 
Table 1. Main characteristics of the included studies. FISH, fluorescence in situ hybridisation; NR, not reported; SB, Southern blot; QDB kit, QIAamp DNA 
Blood kit. 
 
   Study DOR (95% CI) Sens. (95% CI) Spec. (95% CI) PLR (95% CI) NLR (95% CI) 
  Combaret et al. 2002  1160.0 (69.7 – 19320.1) 0.97 (0.83 – 0.99) 0.98 (0.87 – 1.00) 39.6 (5.7 – 275.0) 0.03 (0.01 – 0.24) 
  Gotoh et al. 2005 1581.0 (29.8 – 83804.6) 1.00 (0.80 – 1.00) 1.00 (0.87 – 1.00) 50.4 (3.2 – 785.2) 0.03 (0.00 – 0.49) 
  Combaret et al. 2005  117.0 (14.9 – 918.0) 0.87 (0.62 – 0.96) 0.95 (0.83 – 0.99) 16.5 (4.2 – 64.4) 0.14 (0.04 – 0.51) 
  Combaret et al. 2009  999.8 (57.4 – 17411.0) 0.82 (0.71 – 0.90) 1.00 (0.97 – 1.00) 181.8 (11.4 – 2896.3) 0.18 (0.11 – 0.31) 
  Kojima et al. 2013 891.0 (16.6 – 7940.6) 1.00 (0.81 – 1.00) 1.00 (0.77 – 1.00) 27.2 (1.8 – 413.8) 0.03 (0.00 – 0.47) 
  Yagyu et al. 2016 107.6 (25.3 – 457.4) 0.88 (0.76 – 0.94) 0.94 (0.83 – 0.98) 13.8 (4.6 – 41.4) 0.13 (0.06 – 0.27) 
  Ma et al. 2016 270.0 (22.2 – 3291.3) 0.90 (0.60 – 0.98) 0.97 (0.89 – 0.99) 27.9 (7.0 – 110.8) 0.10 (0.02 – 0.66) 
 
Table 2. DOR, sensitivity, specificity, likelihood ratios with calculated 95% confidence intervals for each study in patients with advanced-stage (stage 3 and 4) 
NB. DOR, diagnostic odds ratio; NLR, negative likelihood ratio; PLR, positive likelihood ratio;  Sens, sensitivity; Spec, specificity. 
  
 
Study DOR (95% CI) Sens (95% CI) Spec (95% CI) PLR (95% CI) NLR (95% CI) 
INSS stage 3      
  Combaret et al. 2002  51.0 (1.70 – 1525.8) 0.80 (0.38 – 0.96) 1.00 (0.68 – 1.00) 13.5 (0.9 – 207.6) 0.265 (0.066 – 1.068) 
  Gotoh et al. 2005 75.0 (1.16 – 4868.6) 1.00 (0.34 – 1.00) 1.00 (0.65 – 1.00) 13.3 (0.9 – 204.7) 0.178 (0.014 – 2.247) 
  Combaret et al. 2005  91.0 (3.05 – 2718.1) 0.75 (0.30 – 0.95) 1.00 (0.83 – 1.00) 28.0 (1.7 – 458.8) 0.308 (0.081 – 1.176) 
  Combaret et al. 2009  152.8 (7.60 – 3060.2) 0.75 (0.51 – 0.90) 1.00 (0.88 – 1.00) 41.2 (2.6 – 651.7) 0.270 (0.122 – 0.596) 
  Kojima et al. 2013 75.0 (1.16 – 4868.6) 1.00 (0.34 – 1.00) 1.00 (0.65 – 1.00) 13.3 (0.9 – 204.7) 0.178 (0.014 – 2.247) 
  Yagyu et al. 2016 66.0 (5.20 – 833.6) 0.92 (0.65 – 0.99) 0.86 (0.60 – 0.96) 6.4 (1.8 – 23.4) 0.097 (0.015 – 0.643) 
  Ma et al. 2016 81.0 (1.14 – 5778.7) 1.00 (0.21 – 1.00) 1.00 (0.77 – 1.00) 21.0 (1.2 – 358.4) 0.259 (0.023 – 2.865) 
INSS stage 4      
  Combaret et al. 2002  1105.0 (43.2 – 28280.7) 1.00 (0.87 – 1.00) 0.97 (0.85 – 0.99) 22.2 (4.6 – 106.4) 0.020 (0.001 – 0.313) 
  Gotoh et al. 2005 999.0 (18.63 – 53582.1) 1.00 (0.77 – 1.00) 1.00 (0.82 – 1.00) 36.6 (2.4 – 565.8) 0.037 (0.002 – 0.558) 
  Combaret et al. 2005  85.0 (6.81 – 1061.0) 0.91 (0.62 – 0.98) 0.89 (0.69 – 0.97) 8.6 (2.3 – 32.5) 0.102 (0.016 – 0.663) 
  Combaret et al. 2009  912.08 (50.0 – 16628.0) 0.85 (0.72 – 0.93) 1.00 (0.96 – 1.00) 142.0 (8.9 – 2258.4) 0.156 (0.077 – 0.316) 
  Kojima et al. 2013 377.0 (6.7 – 21160.0) 1.00 (0.78 – 1.00) 1.00 (0.61 – 1.00) 13.5 (0.9 – 195.9) 0.036 (0.002 – 0.552) 
  Yagyu et al. 2016 211.2 (23.4 – 1908.8) 0.87 (0.73 – 0.94) 0.97 (0.85 – 0.99) 28.7 (4.1 – 198.2) 0.136 (0.060 – 0.308) 
  Ma et al. 2016 188.0 (15.2 – 2324.4) 0.89 (0.57 – 0.98) 0.96 (0.86 – 0.99) 21.8 (5.5 – 86.3) 0.116 (0.018 – 0.736) 
 
Table 3. DOR, sensitivity, specificity and likelihood ratios with calculated 95% confidence intervals for each study in patients sub-grouped by INSS stage. 
DOR, diagnostic odds ratio; NLR, negative likelihood ratio; PLR, positive likelihood ratio;  Sens, sensitivity; Spec, specificity. 
 
 
Table 4. Summary of the diagnostic accuracy of MNA assessment in cfDNA of patients with INSS stage 3 and/or 4 NB with calculated 95% confidence 
intervals. DOR, diagnostic odds ratio; NLR, negative likelihood ratio; PLR, positive likelihood ratio; Sens, sensitivity; Spec, specificity.  
 
INSS stage Sens (95% CI) Spec (95% CI) PLR (95% CI) NLR (95% CI) DOR (95% CI) 
3 and 4 0.908 (0.818 – 0.956) 0.976 (0.940 – 0.991) 38.6 (1.8 – 75.5) 0.094 (0.027 – 0.161) 410.0 (-103.6 – 923.7) 
3 0.832 (0.677 – 0.921) 0.999 (0.109 – 1.000) 1321.2 (-11172.2 – 13814.6) 0.168 (0.048 – 0.288) 7855.2 (-66267.0 – 81977.4) 
4 0.930 (0.838 – 0.972) 0.974 (0.937 – 0.990) 36.4 (3.6 – 69.3) 0.072 (0.009 – 0.134) 508.7 (-85.8 – 1103.2) 
